Skip to main content
Log in

Niraparib: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also under regulatory review in the EU for use in maintenance treatment in patients with platinum-sensitive, recurrent epithelial ovarian cancer who are in response to platinum-based chemotherapy. In the multinational, phase 3 NOVA trial in adult patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly prolonged median progression-free survival, irrespective of the presence or absence of a germline BRCA (gBRCA) mutation and irrespective of the presence or absence of homologous recombinant deficiency. Niraparib is also in development for use in other solid tumours, including breast and prostate cancer. This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jones P, Wilcoxen K, Rowley M, et al. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302–14.

    Article  CAS  PubMed  Google Scholar 

  2. O’Sullivan Coyne G, Chen AP, Meehan R, et al. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77(2):113–30.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tesaro. Tesaro announces expanded development program for niraparib focused on the treatment of front-line metastatic ovarian and lung cancer and metastatic breast cancer. 2017. http://www.tesarobio.com. Accessed 3 Apr 2017.

  4. Tesaro. ZEJULA™ (Niraparib): US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 29 Mar 2017.

  5. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2016. http://www.ema.europa.eu. Accessed 3 Apr 2017.

  6. Tesaro. Tesaro announces acceptance for review of niraparib marketing authorization by EMA. 2016. http://tesarobio.com. Accessed 3 Apr 2017.

  7. Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009;52(22):7170–85.

    Article  CAS  PubMed  Google Scholar 

  8. Bridges KA, Toniatti C, Buser CA, et al. Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014;5(13):5076–86.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Mueller S, Bhargava S, Molinaro AM, et al. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res. 2013;33(3):755–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012;30(6):2113–20.

    Article  CAS  PubMed  Google Scholar 

  11. van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs. 2017. doi:10.1007/s10637-017-0451-2.

    Google Scholar 

  12. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.

    Article  CAS  PubMed  Google Scholar 

  13. Gonzalez-Martin A, Backes FJ, Baumann KH, et al. A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy [abstract no. TPS5606]. J Clin Oncol. 2016;34(Suppl.).

  14. Moore KN, Rimel B, Agarwal S, et al. A Phase 2, open label study of niraparib in women with advanced, relapsed, highgrade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after 3 previous chemotherapy regimens [abstract no. TPS5609]. J Clin Oncol. 2015;33(Suppl. 1).

  15. Balmana J, Tryfonidis K, Audeh W, et al. A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. An EORTC-BIG intergroup study (BRAVO study) [abstract no. OT1-03-05]. Cancer Res. 2016;76(4 Suppl. 1).

  16. Mirza MR, Mortensen CE, DePont Christensen R, et al. A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: the ENGOT-OV24/AVANOVA1 trial [abstract no. 5555]. J Clin Oncol. 2016;34(Suppl.).

  17. Mirza MR, Mortensen CE, Avall-Lundqvist E, et al. ENGOT-OV24-NSGO/AVANOVA: niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinumsensitive epithelial ovarian, fallopian tube, or peritoneal cancer [abstract no. TPS5607]. J Clin Oncol. 2015;33(Suppl. 1).

  18. Konstantinopoulos P, Moore KN, Sachdev JC, et al. Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162) [abstract no. TPS5599]. J Clin Oncol. 2016;34(Suppl.).

  19. Flores JP, Mathew P. Combination therapy with enzalutamide and the poly (ADPribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202 [abstract no. TPS5095]. J Clin Oncol. 2016;34(Suppl.).

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. L.J. Scott is a salaried employee of Adis, Springer SBM.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lesley J. Scott.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Niraparib: First Global Approval. Drugs 77, 1029–1034 (2017). https://doi.org/10.1007/s40265-017-0752-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0752-y

Keywords

Navigation